High-dose isoniazid in the shorter-course multidrug-resistant tuberculosis regimen in the Republic of Moldova

Chesov Dumitru; Ciobanu Nelly; Lange Christoph G.; Heyckendorf Jan; Krudu V.

Conţinutul numărului revistei

Articolul precedent

Articolul urmator

270

SM ISO690:2012

CHESOV, Dumitru, CIOBANU, Nelly, LANGE, Christoph G., HEYCKENDORF, Jan, KRUDU, V.. High-dose isoniazid in the shorter-course multidrug-resistant tuberculosis regimen in the Republic of Moldova. In: European Respiratory Journal, 2017, vol. 50, pp. 1-6. ISSN 0903-1936. DOI: https://doi.org/10.1183/13993003.01340-2017

EXPORT metadate:
Google Scholar
Crossref
CERIF

DataCite
Dublin Core

European Respiratory Journal

Volumul 50 / 2017 / ISSN 0903-1936 /ISSNe 1399-3003

High-dose isoniazid in the shorter-course multidrug-resistant tuberculosis regimen in the Republic of Moldova

DOI:https://doi.org/10.1183/13993003.01340-2017

Pag. 1-6

Chesov Dumitru¹, Ciobanu Nelly², Lange Christoph G.³⁴⁵, Heyckendorf Jan⁶, Krudu V.²

¹ ”Nicolae Testemițanu” State University of Medicine and Pharmacy,
² Institute of Phtysiopneumology „Chiril Draganiuc”,
³ German Centre for Infection Research (DZIF), Partner Site Hamburg-Luebeck-Borstel-Riems,
⁴ University of Lübeck,
⁵ Karolinska Institutet, Stockholm,
⁶ Research Center Borstel

Disponibil în IBN: 8 martie 2022

Rezumat

Since May 2016 the World Health Organization (WHO) has recommended the treatment of multidrug-resistant tuberculosis (MDR-TB) patients with a standardised treatment regimen of 9–12 months duration if patients fulfil specific eligibility criteria [1]. This shorter-course MDR-TB treatment regimen consists of a combination of seven drugs (clofazimine, ethambutol, high-dose isoniazid, kanamycin, moxifloxacin, prothionamide and pyrazinamide) for 4–6 months, followed by four drugs (moxifloxacin, clofazimine, pyrazinamide and ethambutol) for 5 months